• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Ascensia launches Senseonics’ remote monitoring app for Android devices in Europe

March 1, 2022 By Sean Whooley

ascensia diabetes care senseonicsAscensia Diabetes Care announced today that it launched Senseonics‘ (NYSE:SENS) Eversense NOW remote monitoring app for Androids in Europe.

The launch makes remote monitoring capabilities available for all of Senseonics Eversense and Eversense XL continuous glucose monitoring (CGM) users on Android and iOS operating systems in the U.S. and Europe, respectively.

Senseonics developed the Eversense NOW remote monitoring app to allow for real-time glucose data and alerts from Eversense CGM sensor users to be remotely shared. Up to five people can remotely receive updated readings approximately every five minutes, and they can easily view recent trends and alerts.

“The value of remote monitoring in healthcare has never been clearer than in the last two years, with tools providing added peace of mind for users and their support system,” Ascensia Diabetes Care’s Head of the Senseonics CGM business unit Elaine Anderson said in a news release. “Managing diabetes requires continuous monitoring and decision making, and this app makes it easier for friends and family to be part of that process. Having a well-informed support network can reduce the burden placed on people with diabetes, and we are excited to bring this useful tool to all Eversense users in Europe.”

The launch of the CGM in Europe follows last month’s news that Senseonics’ Eversense E3 180-day CGM won FDA approval, extending the wear time from 90 days. Ascensia Diabetes Care, Senseonics’ global commercial partner, will execute the launch, as it is doing with the Eversense NOW remote monitoring app in Europe. Eversense E3 already held European approval before receiving the FDA nod.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Senseonics

IN CASE YOU MISSED IT

  • MiniMed completes split from Medtronic
  • Insulet’s Omnipod Discover data platform begins full US rollout
  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS